Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective RNAi medicines targeting novel biology Dr. Stephen Djedjos appointed Senior Vice President, Clinical Development Moonwalk Biosciences , a biotechnology company developing first-in-class

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres

With $116 million in new funding on tap, BrainChild Bio said Tuesday that it has initiated a pivotal study of the B7-H3-targeted autologous CAR-T cell therapy BCB-276, in the hopes of delivering a much-needed new treatment option for patients with diffuse intrinsic pontine glioma (DIPG). With the current standard-of-care treatment for DIPG limited to palliative focal radiation therapy, median overall survival for this rare and aggressive paediatric brainstem tumour is about 11 months from diagn

Having recently secured FDA approval for the first in a new class of immunomodulatory drugs for multiple myeloma, Bristol Myers Squibb continues to make advances in the field, announcing Tuesday positive data from a registrational trial of its GPRC5D-directed CAR-T cell therapy arlocabtagene autoleucel (arlo-cel). The results come from the Phase II QUINTESSENTIAL study, which investigated arlo-cel in patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). BMS note

Phase 3 study will evaluate safety and efficacy of an investigational once-daily formulation of trientine tetrahydrochloride compared to D-penicillamine as first line treatment in patients with Wilson disease. Sept. 8, 2026 -- Orphalan Inc. today announced the launch of the TRADITiONAL Study, a global, multicenter Phase 3 clinical trial evaluating an investigational once-daily formulation of trientine tetrahydrochloride for the first line treatment of individuals with Wilson disease. The study

Weight-loss giant Eli Lilly joined Moonwalk Biosciences' latest funding round, which will be used to advance the biotech's adipose tissue–directed siRNA therapy into first-in-human studies for obesity in late 2027. In addition to the US pharma, the financing saw participation from Gaorong Ventures, ARCH Venture Partners, Khosla Ventures and Future Ventures. The oversubscribed $70-million series B was co-led by Alpha Wave Ventures and YK Bioventures. The round comes more than two and a half yea

Italian company the Menarini Group has agreed to pay Chinese insulin maker Gan & Lee Pharmaceuticals €62 million ($72 million) up front to collaborate on the registration and commercialization of Gan & Lee’s GLP-1 bofanglutide. Gan & Lee will also be eligible to receive milestone payments of up to €664 million ($771 million), as well as double-digit royalties on sales, according to a release . Menarini will take over regulatory submissions and commercialization in a total of 39 countries, incl

Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. Sept. 7, 2026 -- On September 7, 2026, Shanghai, Cell Stem Cell published online clinical research from CorrectSequence Therapeutics (Correctseq) in collaboration with multiple institutions in a paper titled "Clinical base editing for β-hemoglobinopathies across different genetic backgrounds", demonstrating tha

HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options Del-desiran showed evidence of clinical activity in secondary endpoints and exploratory analyses; full HARBOR dataset to be analyzed and appropriate development path to be determined AOC pipeline continues to advance with FDA priority review granted for delpacibart zotadirsen in DMD44 and planned FDA meeting for delpacibart braxlosiran in FSHD, based

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results. Patients with head and neck cancer who took Inhibrx Biosciences’ OX40 receptor agonist in combination with Merck’s Keytruda responded at a higher rate than those who took Keytruda alone in a Phase 2 trial, clearing the way for the biotech to access what executives estimate is a $50 billion-plus market. IN